p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer

Modern Pathology

Volumn 11, Issue 9, 1998, Pages 823-830

  Têtu, Bernard ^a,b   Brisson, Jacques ^a   Plante, Valérie ^a   Bernard, Pascale ^a  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Breast neoplasms; c erbB 2; Drug resistance; HER2 neu

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; ONCOPROTEIN; PROTEIN P53; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; FEMALE; GENE OVEREXPRESSION; GENETIC MARKER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0344333419     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women Lancet 1992;339:1-15.
2. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:71-85.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ulrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
4. Ravdin PM, Chamness GC. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers: a review. Gene 1995;159:19-27.
5. Têtu B, Brisson J. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer: the influence of the pattern of immunostaining and adjuvant therapy. Cancer 1994;73:2359-65.
6. Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992;10:599-605.
7. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992;10: 1049-6.
8. Bitran JD, Samuels B, Trujillo Y, Klein L, Schroeder L, Martinec J. HER2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (more than 10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy. Clin Cancer Res 1996;2:1509-13.
9. Leitzel K, Teramoto Y, Konrad K, Chinchilli VM, Volas G, Grossberg H, et al. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 1995;13:1129-35.
10. Levine AJ, Momand J, Finlay C. The p53 tumour suppressor gene. Nature 1991;351:453-6.
11. Thor AD, Moore DH II, Edgerton SM, Kawasaki ES, Rehsaus E, Lynch HT, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992;84:845-55.
12. Isola J, Visakorpi T, Holli K, Kallioniemi OP. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 1992;84:1109-14.
13. Allred DC, Clark GM, Elledge R, Fuqua SAW, Brown RW, Chamness GC, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993;85: 200-6.
14. Barnes DM, Dublin EA, Fisher CJ, Levison DA, Millis RR. Immunohistochemical detection of p53 in mammary carcinoma: an important new independent indicator of prognosis? Hum Pathol 1993;24:469-76.
15. Silvestrini R, Daidone MG, Benini E, Faranda A, Tomasic G, Boracchi P, et al. Validation of p53 accumulation as a predictor of distant metastasis at 10 years of follow-up in 1400 node-negative breast cancers. Clin Cancer Res 1996;2:2007-13.
16. Gasparini G, Weidner N, Bevilacqua P, Maluta S, Dalla Palma P, Caffo O, et al. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 1994;12:454-66.
17. Stenmark-Askmalm M, Stal O, Olsen K, Nordenskjold B, South-East Sweden Breast Cancer Group. p53 as a prognostic factor in stage I breast cancer. Br J Cancer 1995;72:715-9.
18. Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L. p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. J Clin Oncol 1995;13:821-30.
19. MacGrogan G, Bonichon F, de Mascarel I, Trojani M, Durand M, Avril A, et al. Prognostic value of p53 in breast invasive ductal carcinoma: an immunohistochemical study on 942 cases. Breast Cancer Res Treat 1995;36:71-81.
20. Bergh J, Norberg T, Sjögren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1995;1:1029-34.
21. Elledge RM, Gray R, Mansour E, Yu Y, Clark GM, Ravdin P, et al. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst 1995;87:1254-6.
22. Aas T, Børresen AL, Geisler S, Smith-Sørensen B, Johnsen H, Varhaug JE, et al. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996;2:811-4.
23. Fisher ER, Sass R, Fisher B. Pathologic findings from the national surgical adjuvant project for breast cancers (protocol no. 4). Cancer 1984;53:712-23.
24. Hsu S-M, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-80.
25. Dressler LG, Bartow SA. DNA flow cytometry in solid tumors: practical aspects and clinical applications. Semin Diagn Pathol 1989;6:55-82.
26. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:453-81.
27. Armitage P. Statistical methods in medical research. New York: Wiley; 1991.
28. Cox DR. Regression models and lifetables (with discussion). J R Stat Soc 1972;34:187-220.
29. Têtu B, Plante V, Brisson J, Bernard P. Prognostic significance of p53 expression in node-positive breast carcinoma [abstract]. Lab Invest 1995;72:27A.
30. Brown R, Clugston C, Burns P, Edlin A, Vasey P, Vojtesek B, et al. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer 1993;55:678-84.
31. Koechli OR, Schaer GN, Seifert B, Hornung R, Haller U, Eppenberger U, et al. Mutant p53 protein associated with chemosensitivity in breast cancer specimens. Lancet 1994; 344:1647-8.
32. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67.
33. Nguyen KT, Liu B, Ueda K, Gottesman MM, Pastan I, Chin K-V. Transactivation of the human multidrug resistance (mdr-1) gene promoter by p53 mutants. Oncol Res 1994;6: 71-7.
34. Linn SC, Honkoop AH, Hoekman K, Vandervalk P, Pinedo HM, Giaccone G. p53 and P-glycoprotein are often coexpressed and are associated with poor prognosis in breast cancer. Br J Cancer 1996;74:63-8.
35. Carlomagno C, Perrone F, Gallo C, Delaurentiis M, Lauria R, Morabito A, et al. c-erbB-2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 1996; 14:2702-8.
36. Tsai CM, Chang KT, Perng RP, Mitsudomi T, Chen MH, Kadoyama C, et al. Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J Natl Cancer Inst 1993;85:897-903.
37. Yu D, Liu B, Tan M, Li J, Wang S-S, Hung M-C. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to taxol via mar-1-independent mechanisms. Oncogene 1996;13:1359-65.
38. Lupu R, Cardillo M, Harris L, Hijazi M, Resenberg K. Interaction between erbB-receptors and heregulin in breast cancer tumor progression and drug resistance. Semin Cancer Biol 1995;6:135-45.
39. Jarvinen TAH, Kononen J, Peltohuikko M, Isola J. Expression of topoisomerase II α is associated with rapid cell proliferation, aneuploidy, and c-erbB-2 overexpression in breast cancer. Am J Pathol 1996;148:2073-82.
40. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330:1260-6.